Cargando...
Targeting opioid dysregulation in depression for the development of novel therapeutics
Since the serendipitous discovery of the first class of modern antidepressants in the 1950’s, all pharmacotherapies approved by the Food and Drug Administration for major depressive disorder (MDD) have shared a common mechanism of action, increased monoaminergic neurotransmission. Despite the widesp...
Guardado en:
| Publicado en: | Pharmacol Ther |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6859062/ https://ncbi.nlm.nih.gov/pubmed/31051197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2019.04.009 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|